36,839 Shares in Vaxcyte, Inc. $PCVX Bought by Corient Private Wealth LP

Corient Private Wealth LP bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 36,839 shares of the company’s stock, valued at approximately $2,141,000.

A number of other hedge funds have also recently bought and sold shares of the stock. NEXTBio Capital Management LP bought a new stake in shares of Vaxcyte in the fourth quarter valued at about $4,406,000. Norges Bank bought a new position in Vaxcyte during the fourth quarter valued at about $56,703,000. Elmind Capital LP bought a new position in Vaxcyte during the fourth quarter valued at about $13,450,000. Seven Fleet Capital Management LP raised its holdings in Vaxcyte by 406.4% in the 1st quarter. Seven Fleet Capital Management LP now owns 128,450 shares of the company’s stock valued at $7,464,000 after acquiring an additional 103,085 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Vaxcyte by 73.4% in the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock valued at $70,711,000 after acquiring an additional 515,209 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Stock Up 1.3%

NASDAQ:PCVX opened at $61.58 on Thursday. The firm has a market capitalization of $9.16 billion, a PE ratio of -8.07 and a beta of 1.22. Vaxcyte, Inc. has a 12-month low of $30.81 and a 12-month high of $65.00. The firm has a 50-day moving average price of $57.98 and a 200 day moving average price of $56.12.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same period last year, the company earned ($1.22) EPS. On average, research analysts expect that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Insider Buying and Selling

In related news, COO Jim Wassil sold 3,477 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $61.07, for a total value of $212,340.39. Following the sale, the chief operating officer owned 155,041 shares of the company’s stock, valued at $9,468,353.87. The trade was a 2.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Harpreet S. Dhaliwal sold 17,000 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total value of $935,000.00. Following the completion of the sale, the insider owned 76,756 shares in the company, valued at $4,221,580. This trade represents a 18.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 121,873 shares of company stock worth $6,671,730 over the last 90 days. Corporate insiders own 3.30% of the company’s stock.

Analyst Ratings Changes

PCVX has been the topic of a number of research reports. Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Finally, Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Vaxcyte currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.